(Q33161299)
Statements
1 reference
Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib (English)
1 reference
Jonathan W Goldman
1 reference
Isett Laux
1 reference
Feng Chai
1 reference
Ronald E Savage
1 reference
Dora Ferrari
1 reference
Edward G Garmey
1 reference
Richard G Just
1 reference
Lee S Rosen
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference